ALK and non-small cell lung carcinoma: Based on phase I and II trials, showing a response rate around 60% in patients with ALK-rearranged NSCLC, crizotinib was approved as second-line treatment for this subset of patients by the US Food and Drug Administration in August 2011 [2] and by the European Medicine Agency in Autumn 2012.